Why This Anthrax Vaccine Study Is Getting a New Cash Injection
Altimmune shares jumped on Wednesday after the company announced that the Biomedical Advanced Research and Development Authority is modifying its existing anthrax vaccine development contract with Altimmune.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Altimmune Inc. (NASDAQ: ALT) shares jumped on Wednesday after the company announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an additional $3.7 million.
The increase in funding is directed primarily toward a Phase 1b clinical trial of NasoShield to evaluate alternative methods of intranasal dosing in humans.
In 2018, BARDA awarded Altimmune $2.5 million for further NasoShield development, including a comparison of different methods of administration of the vaccine in preclinical models.
The data from this study demonstrated that a simple modification to the method of intranasal dose administration had a dramatic impact on the resulting immunogenicity. These results suggest that the 2018 Phase 1 study of NasoShield in healthy adults might have shown a more robust immunogenic effect had a modified administration method been employed.
[nativounit]
The planned Phase 1b clinical trial will evaluate modified methods of intranasal dosing on NasoShield safety and immunogenicity and is expected to start in 2019.
Dr. Vipin K. Garg, Ph.D., president and CEO of Altimmune, commented:
We are extremely pleased that BARDA has made this additional funding available for a clinical study to advance this potentially transformative anthrax vaccine. BARDA has been an outstanding partner for NasoShield and we are excited to continue its development with their support.
Shares of Altimmune traded up about 7% Wednesday morning to $2.28, in a 52-week range of $1.70 to $36.25. The consensus price target is $8.60.
[recirclink id=570322]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
